Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 13/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30760730 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16766890 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14940503 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16767114 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16767113 | 0.84 | HCRTR1 (0.49) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16766769 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16766770 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17580405 | 0.81 | HCRTR1 (0.48) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17580406 | 0.81 | HCRTR1 (0.48) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17580094 | 0.81 | HCRTR1 (0.48) | HCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124488-B2 | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-09-21 | — | — | US | disclosed |
| EP-3619199-B1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210114997-A1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-2776430-B1 | 2- (1,2,3-TRIAZOL-2-YL) BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL) PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-9150566-B2 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2776430-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013068935-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885CYP3A4 1336/4885 |
| US-11124488-B2 | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives | KCNK5, KCNJ2, KCNK2 | HCRTR1 4534/4885HCRTR2 3339/4885CYP3A4 295/4885 |
| US-20210114997-A1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | KCNK5, KCNJ2, KCNK2 | HCRTR1 4534/4885HCRTR2 3339/4885CYP3A4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.